Treatment with JAK2/STAT3 pathway inhibitors attenuated experimental AAA progression by reducing the expression of pro-inflammatory cytokines and matrix metalloproteinases as well as inflammatory cell infiltration [16,17]. The gene discussed is STAT3; the disease is triple-A syndrome.